Skip to main content
Premium Trial:

Request an Annual Quote

Leica Biosystems, Molecular Instruments Partner on Tissue Research Products

This story has been updated from a previous version to clarify the nature of the partnership between Leica and Molecular Instruments.

NEW YORK – Danaher subsidiary Leica Biosystems announced on Wednesday a deal with Molecular Instruments aimed at the detection of RNA and protein targets on the same tissue sample, enabling spatial insights in cancer research. 

Under the agreement, the partners will combine Molecular Instruments' HCR Pro RNA-ISH imaging technology with Leica's existing Bond immunohistochemistry and immunofluorescence protocols, Leica said in a statement. The products are intended for research use only.

HCR Pro RNA-ISH uses HCR signal amplification platform for brightfield and fluorescent imaging of RNA targets in formalin-fixed, paraffin-embedded tissue samples. Pairing this capability with the scalability of the Bond RX and Bond RXm staining systems will allow researchers to extract even more information from one sample, preserving precious tissue, Leica said.

"We are thrilled to introduce this important addition to our portfolio of partner assays, further solidifying Bond RX as a leader in research staining automation," Karan Arora, Leica's senior VP of advanced assays and pharma services, said in a statement. "This collaboration with Molecular Instruments is a pivotal step in making this innovative technology more accessible and scalable for cancer research. By combining innovation and automation, we empower researchers with a powerful platform to unlock deeper insights into RNA expression and advance our understanding of cancer biology."

Financial and other terms of the deal were not disclosed.